Based in the Netherlands, Meneldor focuses on investing in companies that develop new bio or chemical molecular entities with strong intellectual property, address significant medical needs, and operate in attractive markets. They thoroughly evaluate the science behind potential portfolio companies and consider factors such as competition, risk, management, and financial needs before making investments. Meneldor's current holdings include companies working on drug therapies for acute Graft vs Host disease, novel anti-viral drugs, automated aptamer discovery platforms, and fluorescent drugs for targeted cell killing.